Propofol metabolites in man following propofol induction and maintenance

British Journal of Anaesthesia

Volumn 88, Issue 5, 2002, Pages 653-658

  Favetta, P ^a   Degoute, C S ^b   Perdrix, J P ^b   Dufresne, C ^a   Boulieu, R ^a,c   Guitton, J ^d,e  

^a Institut des Sciences Pharmaceutiques et Biologiques   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c HÔPITAL NEUROLOGIQUE   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e INSERM   (France)

Author keywords

Anaesthetics i.v., propofol; Pharmokinetics, propofol

Indexed keywords

ALPRAZOLAM; ANESTHETIC AGENT; ANTIBIOTIC AGENT; CEFAZOLIN; CEFTRIAXONE; CYTOCHROME P450; DOMPERIDONE; DRUG METABOLITE; GLUCURONIDE; HYDROXYZINE; KETOPROFEN; PARACETAMOL; PROPOFOL; REMIFENTANIL; RINGER SOLUTION; SULFATE;

ADULT; AGED; ANESTHESIA INDUCTION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BOLUS INJECTION; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG INFUSION; DRUG METABOLISM; FEMALE; GENDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLIC CLEARANCE RATE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POPULATION RESEARCH; PREMEDICATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ULTRAVIOLET RADIATION; URINALYSIS;

EID: 0036257688     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/88.5.653     Document Type: Article

References (25)

1. Propofol-An update of its use in anaesthesia and conscious sedation
2. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation
3. Pharmacokinetic implications for the clinical use of propofol
4. Use of proton NMR spectroscopy to measure propofol metabolites in the urine of the female Caucasian patient
5. Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of C-propofol
6. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol
7. Detection of new propofol metabolites in human using GC-MS and LC-MS techniques
8. Clinical pharmacology study. The metabolism of propofol in man
9. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes
10. HPLC assay to detect hydroxylate and conjugate metabolites of propofol in human urine
11. Species differences in blood profiles, metabolism and excretion of 14C-propofol after intravenous dosing to rat, dog and rabbit
12. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGTI gene family
13. Genetic analysis of the human cytochrome P450 CYP2C9 locus
14. Determination of remifentanil in human blood by liquid-liquid extraction and capillary GC-HRMS-SIM using a deuterated internal standard
15. Transformation reactions: Glucuronidation
16. Disposition of propofol administered as constant rate intravenous infusions in humans
17. Bispectral index, predicted and measured drug levels of target-controlled infusions of remifentanil and propofol during laparoscopic cholecystectomy and emergence
18. Propofol clearance is decreased by remifentanil
19. Hepatic and extrahepatic disposition of propofol in patients undergoing coronary bypass surgery
20. Effect of i.v. anaesthesia with propofol on drug distribution and metabolism in the dog
21. Disposition of propofol in patients undergoing surgery. A comparison in men and women
22. The influence of environmental and genetic factors on CYP2D6. CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes
23. Pharmacokinetics of propofol (diprivan) in elderly patients
24. Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?
25. Alfentanil pharmacokinetics and metabolism in humans